Towa Pharmaceutical Co., Ltd. (TYO: 4553)
Japan
· Delayed Price · Currency is JPY 3,220.00
-60.00 (-1.83%)
Jan 15, 2025, 3:45 PM JST
Towa Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Revenue | 243,942 | 227,934 | 208,859 | 165,615 | 154,900 | 110,384 | Upgrade
|
| Revenue Growth (YoY) | 8.06% | 9.13% | 26.11% | 6.92% | 40.33% | 5.02% | Upgrade
|
| Cost of Revenue | 155,886 | 146,551 | 136,145 | 95,429 | 89,448 | 59,738 | Upgrade
|
| Gross Profit | 88,056 | 81,383 | 72,714 | 70,186 | 65,452 | 50,646 | Upgrade
|
| Selling, General & Admin | 53,568 | 50,405 | 51,825 | 39,381 | 34,842 | 25,932 | Upgrade
|
| Research & Development | 13,242 | 13,242 | 15,265 | 11,488 | 10,642 | 8,566 | Upgrade
|
| Operating Expenses | 66,898 | 63,735 | 67,199 | 51,648 | 45,523 | 34,475 | Upgrade
|
| Operating Income | 21,158 | 17,648 | 5,515 | 18,538 | 19,929 | 16,171 | Upgrade
|
| Interest Expense | -1,311 | -947 | -635 | -230 | -190 | -131 | Upgrade
|
| Interest & Investment Income | 203 | 106 | 25 | 14 | 29 | 86 | Upgrade
|
| Currency Exchange Gain (Loss) | 2,553 | 1,593 | 1,181 | 795 | 770 | 722 | Upgrade
|
| Other Non Operating Income (Expenses) | 736 | 527 | 905 | 725 | 527 | 470 | Upgrade
|
| EBT Excluding Unusual Items | 23,339 | 18,927 | 6,991 | 19,842 | 21,065 | 17,318 | Upgrade
|
| Gain (Loss) on Sale of Investments | -249 | -222 | -20 | -563 | -45 | -274 | Upgrade
|
| Gain (Loss) on Sale of Assets | 63 | 225 | -46 | 96 | 97 | -6 | Upgrade
|
| Asset Writedown | 1,237 | 5,550 | -2,282 | 2,896 | -2,388 | 3,672 | Upgrade
|
| Other Unusual Items | -24 | -21 | -38 | -26 | -1 | -1 | Upgrade
|
| Pretax Income | 24,366 | 24,459 | 4,605 | 22,245 | 18,728 | 20,709 | Upgrade
|
| Income Tax Expense | 8,591 | 8,286 | 2,404 | 6,331 | 4,770 | 6,206 | Upgrade
|
| Net Income | 15,775 | 16,173 | 2,201 | 15,914 | 13,958 | 14,503 | Upgrade
|
| Net Income to Common | 15,775 | 16,173 | 2,201 | 15,914 | 13,958 | 14,503 | Upgrade
|
| Net Income Growth | 144.12% | 634.80% | -86.17% | 14.01% | -3.76% | 7.63% | Upgrade
|
| Shares Outstanding (Basic) | 49 | 49 | 49 | 49 | 49 | 49 | Upgrade
|
| Shares Outstanding (Diluted) | 49 | 49 | 49 | 50 | 51 | 53 | Upgrade
|
| Shares Change (YoY) | -0.00% | -0.00% | -2.19% | -1.86% | -3.57% | 0.01% | Upgrade
|
| EPS (Basic) | 320.49 | 328.58 | 44.72 | 323.35 | 283.62 | 294.72 | Upgrade
|
| EPS (Diluted) | 320.49 | 328.58 | 44.72 | 316.19 | 271.93 | 272.61 | Upgrade
|
| EPS Growth | 144.12% | 634.82% | -85.86% | 16.27% | -0.25% | 7.62% | Upgrade
|
| Free Cash Flow | -9,982 | -29,639 | -26,187 | 10,989 | 2,871 | 14,615 | Upgrade
|
| Free Cash Flow Per Share | -202.80 | -602.17 | -532.02 | 218.36 | 55.99 | 274.85 | Upgrade
|
| Dividend Per Share | 60.000 | 60.000 | 60.000 | 57.000 | 44.000 | 44.000 | Upgrade
|
| Dividend Growth | 0% | 0% | 5.26% | 29.55% | 0% | 22.79% | Upgrade
|
| Gross Margin | 36.10% | 35.70% | 34.81% | 42.38% | 42.25% | 45.88% | Upgrade
|
| Operating Margin | 8.67% | 7.74% | 2.64% | 11.19% | 12.87% | 14.65% | Upgrade
|
| Profit Margin | 6.47% | 7.10% | 1.05% | 9.61% | 9.01% | 13.14% | Upgrade
|
| Free Cash Flow Margin | -4.09% | -13.00% | -12.54% | 6.64% | 1.85% | 13.24% | Upgrade
|
| EBITDA | 39,988 | 35,536 | 24,924 | 29,492 | 30,354 | 24,456 | Upgrade
|
| EBITDA Margin | 16.39% | 15.59% | 11.93% | 17.81% | 19.60% | 22.16% | Upgrade
|
| D&A For EBITDA | 18,830 | 17,888 | 19,409 | 10,954 | 10,425 | 8,285 | Upgrade
|
| EBIT | 21,158 | 17,648 | 5,515 | 18,538 | 19,929 | 16,171 | Upgrade
|
| EBIT Margin | 8.67% | 7.74% | 2.64% | 11.19% | 12.87% | 14.65% | Upgrade
|
| Effective Tax Rate | 35.26% | 33.88% | 52.20% | 28.46% | 25.47% | 29.97% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.